title: [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
abstract: OBJECTIVE
  To evaluate the influence of highly active antiretroviral therapy (HAART) on bone mineral density (BMD) in HIV/AIDS patients and correlating clinical factors.
  
  
  METHODS
  149 HIV patients were divided into 3 groups:untreated group with 41 patients, HAART for 1-2 years group with 60 patients, HAART over 5 years group with 48 patients; 20 healthy individuals included as a control group. BMD-T score and BMD-Z score were measured by dual-energy X-ray absorptiometry (DXA).
  
  
  RESULTS
  BMD-Z score of right hip was significantly lower in HAART over 5 years group (0.16 ± 0.82) than untreated group (0.61 ± 1.09) (P = 0.039). BMD-Z score of right femoral neck was significantly lower in HAART over 5 years group (-0.002 ± 0.87) than untreated group (0.55 ± 1.08) (P = 0.012). BMD-Z score of HAART for 1-2 years group was not significantly decreased. BMD-Z score of right hip and right femoral neck were correlated negatively with HAART duration. The incidence of osteopenia/osteoporosis in HAART for 1 - 2 years group (31.7%) and HAART over 5 years group (31.3%) were significantly higher than untreated group (12.2%) (P < 0.05). Body weight was revealed as a risk factor of osteopenia/osteoporosis.
  
  
  CONCLUSIONS
  BMD of right hip and right femur neck were significantly lower in HAART over 5 years group. The incidence of osteopenia/osteoporosis were significantly higher in patients receiving HAART. BMD were correlated negatively with HAART duration. Patients in long-term HAART combined with risk factors such as old age or lower body weight should be checked by DXA regularly.
authors.affiliation: Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Yuan-bo
authors.initials: YB
authors.lastname: Su
authors.forename: Jing
authors.initials: J
authors.lastname: Xie
authors.forename: Yang
authors.initials: Y
authors.lastname: Han
authors.forename: Zhi-feng
authors.initials: ZF
authors.lastname: Qiu
authors.forename: Yan-ling
authors.initials: YL
authors.lastname: Li
authors.forename: Xiao-jing
authors.initials: XJ
authors.lastname: Song
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
authors.forename: Tai-sheng
authors.initials: TS
authors.lastname: Li
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000209:etiology; D016022:Case-Control Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology*; D012307:Risk Factors